Neither Gibbs nor her firm own any shares of Herbalife and she advises her clients to avoid it as well. She believes regulatory risks outweigh its seemingly attractive valuation.
Courtesy of S&P Capital IQ
Investors who insist on trading Herbalife may find the charts difficult to use, according to Richard Ross, global technical strategist at Auerbach Grayson.
“Admittedly, technical analysis might not be the ideal tool to try to break down Herbalife’s future because it’s so binary or event driven,” said Ross, a “Talking Numbers” contributor. “It’s really all or nothing here. We could wake up one day and the company could be deemed a fraud or we could wake up and these accusations by Bill Ackman and others could be set aside and the stock could soar.”
“If you’re looking to play this volatility, you would be a buyer above that 200-day moving average,” said Ross. “Use that $65 as your protective stop. And similarly, if we broke down beneath that $65 level, you could be a seller—or even a short seller—of this stock and you want to use, once again, that $65 level as your protective stop on the upside.”
But Ross emphasizes that even if one does buy in, this is not a stock for the long run.
“Ultimately, hedge fund managers like Ackman could be right about this stock being a fraud,” Ross said. “But in the short term, due to that short interest, due to the volatility, they could be very wrong. So take a very small position here and manage that risk.”
To see the full discussion on Herbalife, with Gibbs on the fundamentals and Ross on the technicals, watch the above video.